Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human DLC1 Antibodies:
anti-Mouse (Murine) DLC1 Antibodies:
anti-Rat (Rattus) DLC1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal DLC1 Primary Antibody for IHC (p), IHC - ABIN268701
Ko, Yeung, Wong, Chan, Poon, Ng, Yam: Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. in Liver international : official journal of the International Association for the Study of the Liver 2009
Show all 2 Pubmed References
Human Polyclonal DLC1 Primary Antibody for IHC, IHC (p) - ABIN4305321
Muehlich, Hampl, Khalid, Singer, Frank, Breuhahn, Gudermann, Prywes: The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1. in Oncogene 2012
Human Polyclonal DLC1 Primary Antibody for IHC, ELISA - ABIN185264
Wilson, McGlinn, Marsh, Evans, Arnold, Wright, Biden, Young, Wainwright, Wicking, Chenevix-Trench: Sequence variants of DLC1 in colorectal and ovarian tumours. in Human mutation 2000
Show all 2 Pubmed References
DLC1 (show DYNLL1 Antibodies) is the predominant family member expressed in several normal tissues, and its expression is preferentially reduced in common cancers at these sites.
Fluctuation of reactive oxygen species inhibited migration through reducing the interaction between DLC1 (show DYNLL1 Antibodies) and CAV-1 (show CAV1 Antibodies).
IGF2 may exert its oncofunction, at least partly, through its parasitic miR (show MLXIP Antibodies)-483 which suppressed DLC-1 (show DYNLL1 Antibodies) in colorectal cancer cells. DLC-1 (show DYNLL1 Antibodies) expression was decreased in colorectal cancer tissues and diminished through transient transfection with miR (show MLXIP Antibodies)-483-3p.
The results of this study showed for the first time that CpGs of the DLC1 (show DYNLL1 Antibodies)-v1 alternative promoter is frequently hypermethylated in tumors of meningeal origin.
Receptor tyrosine kinase (show RET Antibodies) activation of RhoA (show RHOA Antibodies) is mediated by AKT (show AKT1 Antibodies) phosphorylation of DLC1 (show DYNLL1 Antibodies).
Study suggests a mechanism for EZH2 (show EZH2 Antibodies)-H3K27me3 epigenetic repression of DLC1 (show DYNLL1 Antibodies) and multilayered regulation of DLC1 (show DYNLL1 Antibodies)/Rho/ROCK signaling by EZH2 (show EZH2 Antibodies), and advocated the significant pro-metastatic role of EZH2 (show EZH2 Antibodies) via repressing tumor and metastasis suppressors.
The results identify DLC1 (show DYNLL1 Antibodies) as an activator of white and brown adipocyte differentiation, and provide a molecular link between PPARgamma (show PPARG Antibodies) and Rho pathways.
DLC-1 (show DYNLL1 Antibodies) has a positive regulatory role in endothelial cell angiogenesis.
Subsequent studies have demonstrated that DLC-1 (show DYNLL1 Antibodies) is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 (show DYNLL1 Antibodies) as a potential tumor suppressor. [review]
Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7 (show FBXW7 Antibodies)), and cadherin-6 (CDH6 (show CDH6 Antibodies)) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR (show MLXIP Antibodies)-129-2 and members of the miR (show MLXIP Antibodies)-200 family (miR (show MLXIP Antibodies)-200a, miR (show MLXIP Antibodies)-200b, and miR (show MLXIP Antibodies)-429) as novel tumor suppressors and oncomiRs, respectively, in CC
DLC-1 has a positive regulatory role in endothelial cell angiogenesis.
studies demonstrate that TNS1 (show TNS1 Antibodies) binds to DLC1 and fine-tunes its RhoGAP (show ARHGAP1 Antibodies) activity toward RhoA (show RHOA Antibodies) and that the TNS1 (show TNS1 Antibodies)-DLC1-RhoA (show RHOA Antibodies) signaling axis is critical in regulating cellular functions that lead to angiogenesis
Loss of expression of only Dlc1 isoform 2 may be sufficient for the development of thymic tumors and metastasis.
Several genes and biochemical activities collaborate with the inactivation of DLC1 to give rise to cell transformation in MEFs, and the identified genes are relevant to human tumors with low DLC1 expression.
The Dlc1 deficient cells showed altered cytoskeleton structure, increased RhoA (show RHOA Antibodies) activity and cellular migration.
DLC-1-/- embryos had defects in the neural tube, brain, heart, and placenta
Our data validate DLC1 as a potent tumor suppressor gene and suggest that its loss creates a dependence on the RhoA (show RHOA Antibodies) pathway that may be targeted therapeutically.
This gene encodes a GTPase-activating protein (GAP) that is a member of the rhoGAP family of proteins which play a role in the regulation of small GTP-binding proteins. GAP family proteins participate in signaling pathways that regulate cell processes involved in cytoskeletal changes. This gene functions as a tumor suppressor gene in a number of common cancers, including prostate, lung, colorectal, and breast cancers. Multiple transcript variants due to alternative promoters and alternative splicing have been found for this gene.
Rho-GTPase-activating protein 7
, START domain-containing protein 12
, StAR-related lipid transfer (START) domain containing 12
, deleted in liver cancer 1 protein
, deleted in liver cancer 1 variant 2
, rho GTPase-activating protein 7
, rho-type GTPase-activating protein 7
, deleted in liver cancer 1
, deleted in liver cancer 1 protein homolog
, stAR-related lipid transfer protein 12
, rho GTPase-activating protein 7-like
, Deleted in liver cancer 1 protein homolog
, Rho-type GTPase-activating protein 7
, rho GTPase activating protein 7